课题基金 / 基金详情

Defining the role of CDK6 and DNA repair pathways in tumorigenesis and identify CDK4/6-dependent synthetic lethal vulnerabilities in triple negative breast cancer.

Defining the role of CDK6 and DNA repair pathways in tumorigenesis and identify CDK4/6-dependent synthetic lethal vulnerabilities in triple negative breast cancer.
定义 CDK6 和 DNA 修复途径在肿瘤发生中的作用,并确定三阴性乳腺癌中依赖于 CDK4/6 的合成致死漏洞。
批准号:
461405
负责人:
Lebrun Jean-Jacques
金额:
$76.24万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-03-01 至 2027-03-01

项目摘要

项目成果

Lebrun Jean-Jacques的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Metastatic cancers are the most aggressive cancers, accounting for 90% of all cancer-related deaths. Radiation as well as chemotherapy are not effective enough to fight against these types of cancers. Our lab is studying triple-negative breast cancers (TN
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting a novel dual-specificity cell cycle inhibitor, KP108 as a therapeutic approach for metastatic breast cancer
  • 批准号:
    469188
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.89万
  • 财政年份:
    2022
  • 负责人:
    Lebrun Jean-Jacques
  • 依托单位:
Defining the role of CDK6 and DNA repair pathways in tumorigenesis and identify CDK4/6-dependent synthetic lethal vulnerabilities in triple negative breast cancer.
  • 批准号:
    455857
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Lebrun Jean-Jacques
  • 依托单位:
Characterization of the TGFß microRNAome - implications for new biomarkers and therapeutic targets in human cancer
CDK4 regulation of breast cancer stem cells - A novel prognostic marker and therapeutic target for triple-negative breast cancer and chemotherapy-resistant tumors.
  • 批准号:
    345984
  • 项目类别:
    Operating Grants
  • 资助金额:
    $71.57万
  • 财政年份:
    2016
  • 负责人:
    Lebrun Jean-Jacques
  • 依托单位:
海外基金